Results 131 to 140 of about 766 (168)

Novel treatment strategies in acute myeloid leukemia. [PDF]

Blood Res
Simkhada S, Joshi U, Dhakal P.
europepmc   +1 more source

Case Report: Early diagnostic precision matters: navigating therapeutic uncertainty in pediatric BPDCN illustrated by misdiagnosis sequelae and fleeting CAR-T response. [PDF]

Front Pediatr
Chen X, Wang J, Hao W, Qu Y, Wang X, Jiang H, Zhang W.   +6 more
europepmc   +1 more source

BPDCN: state of the art. [PDF]

Hematology Am Soc Hematol Educ Program
Pemmaraju N.
europepmc   +1 more source

Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Blood Adv
Khalife-Hachem S, Pages A, Akoury E, Bonnet S, Birsen R, Busquet C, Contejean A, Danu A, de Botton S, de Charette M, Dumas PY, Jaccard A, Marfaing-Koka A, Willekens C, Deconinck E, Ghez D.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm

Hematology/Oncology Clinics of North America, 2020
Tagraxofusp, a CD123-targeted immunotoxin, is the first FDA-approved treatment for patients 2 years and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN). It has been shown to be safe and effective in treatment-naïve and previously treated adult patients, with high rates of successful bridging to hematopoietic stem cell transplantation ...
Naveen Pemmaraju, Danielle Hammond
exaly   +3 more sources

Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm

Leukemia and Lymphoma
Patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) have limited treatment options. Tagraxofusp is the only drug approved for BPDCN.
Marco Herling, Ann-Kristin Schmälter, Emanuele Angelucci   +2 more
exaly   +2 more sources

Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome.

Cardio-Oncology, 2021
[Figure: see text]
Jose Banchs, Juan Lopez-Mattei, Naveen Pemmaraju   +2 more
exaly   +3 more sources

Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression [PDF]

Journal of Hematopathology, 2021
AbstractTagraxofusp, a CD123-based-targeted immunotherapy, was recently approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) with excellent response. Also, a subset of BPDCN shows resistance to tagraxofusp. These resistant cases continue to express CD123, which forms the basis of the continued utility of tagraxofusp in newer ...
Mehdi Nassiri, Rohit Gulati, Tareq Salous   +2 more
exaly   +3 more sources

Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm

Expert Review of Anticancer Therapy, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy that previously lacked standardized therapeutic approaches. CD123 (interleukin-3 receptor alpha unit) is highly expressed in many hematologic malignancies, including BPDCN. Tagraxofusp-ezrs (tagraxofusp from herein) is an agent that consists of interleukin-
Naveen Pemmaraju, Deborah McCue
exaly   +3 more sources